EyePoint Pharma Files Routine 8-K, Confirms Nasdaq Listing

Ticker: EYPT · Form: 8-K · Filed: Jan 10, 2024 · CIK: 1314102

Eyepoint Pharmaceuticals, Inc. 8-K Filing Summary
FieldDetail
CompanyEyepoint Pharmaceuticals, Inc. (EYPT)
Form Type8-K
Filed DateJan 10, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: corporate-update, compliance, administrative

TL;DR

**EYPT filed a routine 8-K, no new news, just corporate info update.**

AI Summary

EyePoint Pharmaceuticals, Inc. filed an 8-K on January 10, 2024, indicating a routine update to its corporate information, specifically regarding its business address at 480 Pleasant Street, Watertown, Massachusetts, 02472. This filing also confirms its trading symbol EYPT on The Nasdaq Global Market. For investors, this filing is a standard procedural update and does not contain new financial results or significant operational changes that would directly impact the stock's value, but it confirms the company's continued compliance with SEC reporting requirements.

Why It Matters

This filing is a standard procedural update, confirming EyePoint Pharmaceuticals' current business address and its listing on The Nasdaq Global Market under the ticker EYPT. It signals ongoing compliance but offers no new financial or operational insights for investors.

Risk Assessment

Risk Level: low — This 8-K filing is purely administrative, updating corporate information without disclosing any material events that would introduce new risks.

Analyst Insight

A smart investor would note this as a routine compliance filing and understand it contains no new material information to influence investment decisions. No immediate action is warranted based solely on this 8-K.

Key Players & Entities

  • EyePoint Pharmaceuticals, Inc. (company) — the registrant filing the 8-K
  • January 10, 2024 (date) — date of earliest event reported and filing date
  • 480 Pleasant Street, Watertown, Massachusetts, 02472 (address) — principal executive offices of EyePoint Pharmaceuticals
  • EYPT (company) — trading symbol for EyePoint Pharmaceuticals
  • The Nasdaq Global Market (market) — exchange where EyePoint Pharmaceuticals' common stock is registered

FAQ

What is the purpose of this 8-K filing by EyePoint Pharmaceuticals, Inc.?

This 8-K filing by EyePoint Pharmaceuticals, Inc. is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting on the date of the earliest event as January 10, 2024. It primarily serves to update corporate information, including the company's principal executive offices and its listing on The Nasdaq Global Market.

What is the current business address of EyePoint Pharmaceuticals, Inc. as stated in the filing?

As stated in the filing, the current business address of EyePoint Pharmaceuticals, Inc. is 480 Pleasant Street, Watertown, Massachusetts, 02472.

On which stock exchange is EyePoint Pharmaceuticals, Inc. common stock registered, and what is its trading symbol?

EyePoint Pharmaceuticals, Inc. common stock, with a par value of $0.001, is registered on The Nasdaq Global Market under the trading symbol EYPT.

What is the date of the earliest event reported in this 8-K filing?

The date of the earliest event reported in this 8-K filing is January 10, 2024.

Does this 8-K filing contain any information about financial results or operational changes?

No, this 8-K filing does not contain any information about financial results or significant operational changes. It is a routine administrative filing updating corporate details.

Filing Stats: 520 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2024-01-10 07:05:18

Key Financial Figures

  • $0.001 — ch registered Common Stock, par value $0.001 EYPT The Nasdaq Global Market Ind

Filing Documents

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On January 10, 2024, EyePoint Pharmaceuticals, Inc. (the “Company”) posted an updated investor presentation on its website at www.eyepointpharma.com which included certain financial information as of December 31, 2023. A copy of the presentation is filed herewith as Exhibit 99.1 and is incorporated by reference herein.

01 Other Events

Item 8.01 Other Events. On January 10, 2024, the Company issued a press release announcing the first patient dosed in phase 2 of the clinical trial of EYP-1901 for the treatment of diabetic macular edema (DME). A copy of the press release is attached hereto as Exhibit 99.2 and incorporated by reference herein. The information set forth in Item 2.02 of this Current Report on Form 8-K is incorporated by reference into this Item 8.01.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 99.2 Investor Presentation of EyePoint Pharmaceuticals, Inc. dated January 10, 2024 Press Release of EyePoint Pharmaceuticals, Inc. dated January 10, 2024 104 Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EYEPOINT PHARMACEUTICALS, INC. Date: January 10, 2024 By: /s/ George O. Elston George O. Elston Executive Vice President and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.